Aquestive Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
30 Technology Dr, Warren, New Jersey, 07...Phone Number
(908) 941-1900Website
www.aquestive.comRevenue
$54.1 MillionStock Symbol
AQSTIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four commercialized products marketed by its licensees in the U.S. and around the world, and is the exclusive manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Aquestive is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an earlier stage epinephrine prodrug topical gel product candidate for possible various dermatology conditions.Explore more
Aquestive Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aquestive Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Aquestive Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Aquestive Therapeutics is spiking on competitors!
Earning: See what the market has to say on Aquestive Therapeutics recently announced quarterly report
Check if Aquestive Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Aquestive Therapeutics launches new products
Click to see if Aquestive Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Aquestive Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Aquestive Therapeutics
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Aquestive Therapeutics
Find 2 more new buyers
Compare Similar Companies to Aquestive Therapeutics
Compare insights from companies similar to Aquestive Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aquestive Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aquestive Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aquestive Therapeutics.
Aquestive Therapeutics financials insights
Gather financial insights about Aquestive Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Other Financing Round
$2.5M
Other Financing Round
$20M
2016
Debt
$50M
2019
Debt
$70M
2025
Other Financing Round
$75M
Aquestive Therapeutics Tech Stack
A closer look at the technologies used by Aquestive Therapeutics
See more technologies
Most Recent Scoops
Earnings
Aquestive Therapeutics has reported selling, general, and administrative expenses of $25 million for the six months ended June 30, 2026, a decrease from $31.8 million for the six months ended June 30, 2025, primarily due to lower commercial spending of approximately $4.5 million, the one-time Anaphylm PDUFA fee of $4.3 million in the prior year period, lower legal fees of approximately $1.3 million, and lower regulatory and licensing fees of approximately $1.9 million, partially offset by higher severance costs of approximately $2 million, higher personnel costs of approximately $1.4 million, and higher share-based compensation of approximately $1.8 million.
Earnings, Accounting, Financial Reporting, Finance, Financial Operations
Project
Aquestive Therapeutics has completed the necessary studies for the Anaphylm resubmission and remains on track to resubmit to the FDA before the end of the current quarter, less than eight months after receiving a complete response letter. The resubmission will include results from the company's most recent human factors validation study, covering participant interactions with the improved packaging and instructions for use.
Product Development, Pharmaceuticals, Clinical Operations
Earnings
Aquestive Therapeutics has reported selling, general, and administrative expenses of $14.1 million for Q2 2026, an increase from $12.7 million in Q2 2025, primarily driven by higher legal fees of approximately $2.1 million, higher severance costs of approximately $1.4 million, higher personnel costs of approximately $0.9 million, and higher share-based compensation of approximately $0.3 million, partially offset by lower commercial spending of approximately $2.6 million and lower regulatory and licensing fees of approximately $1.2 million.
Spending/Investment, Personnel Moves, Accounting, Legal Affairs, Financial Reporting, Finance
Earnings
Aquestive Therapeutics has reported a net loss of $30.9 million, or $0.25 per share (basic and diluted), for the six months ended June 30, 2026, compared to a net loss of $36.5 million, or $0.37 per share, for the six months ended June 30, 2025; excluding the one-time loss on extinguishment of debt, net loss for the period was $19.2 million.
Earnings, Finance
Person-Based
Pharmaceuticals
Aquestive Therapeutics News & Media
Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in four upcoming investor conferences in September 2026 as follows:Aquestive (AQST) Q2 2026 Earnings Call Transcript
Revenue grew 38% year-over-year to $13.8 million as Anaphylm resubmission nears.Aquestive Therapeutics Inc (AQST) (Q2 2026) Earnings Call Highlights: Anaphylm Resubmission on ...
Company advances toward Q3 NDA resubmission with improved human factors data, while total revenue climbs to $13.8 million and adjusted EBITDA loss narrows to $5.2 million.Aquestive Therapeutics Q2 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) said it plans to resubmit its new drug application for Anaphylm, its epinephrine sublingual film candidate for type 1 allergic reactions including anaphylaxis, before the end of the third quarter after completing studies requested by the U.S. Food and Drug Admini
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aquestive Therapeutics
Sign Up For FreeTo access detailed company insights
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administered products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. Aquestive has four comme... Read More
